In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature

Abstract

Targeted delivery of bioactive molecules to diseased organs or tissues by means of binding molecules specific to markers of diseases represents a promising area of pharmaceutical intervention. The availability of markers of pathology, ideally accessible from the vasculature, is crucial for such strategies. To this aim, here we present a protocol based on terminal perfusion of mice with a reactive ester derivate of biotin that enables the covalent modification of proteins readily accessible from the bloodstream. Biotinylated proteins from total organ or tissue extracts are (i) purified on streptavidin resin in the presence of strong detergents, (ii) digested on the resin and (iii) subjected to proteomic analysis. This technology is applicable to comparative proteomic investigations of differentially expressed, accessible proteins in numerous animal models having different physiological and pathological processes.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2: Experimental setup of in vivo perfusion.

References

  1. 1

    Neri, D. & Bicknell, R. Tumour vascular targeting. Nat. Rev. Cancer 5, 436–446 (2005).

  2. 2

    Huang, X. et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275, 547–550 (1997).

  3. 3

    Wu, A.M. & Senter, P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137–1146 (2005).

  4. 4

    Adams, G.P. & Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147–1157 (2005).

  5. 5

    Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118–129 (2001).

  6. 6

    Winter, G., Griffiths, A.D., Hawkins, R.E. & Hoogenboom, H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433–455 (1994).

  7. 7

    Silacci, M. et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5, 2340–2350 (2005).

  8. 8

    Collins, J., Horn, N., Wadenback, J. & Szardenings, M. Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries. J. Biotechnol. 74, 317–338 (2001).

  9. 9

    Brody, E.N. & Gold, L. Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74, 5–13 (2000).

  10. 10

    Erlanson, D.A. et al. In situ assembly of enzyme inhibitors using extended tethering. Nat. Biotechnol. 21, 308–314 (2003).

  11. 11

    Melkko, S., Scheuermann, J., Dumelin, C.E. & Neri, D. Encoded self-assembling chemical libraries. Nat. Biotechnol. 22, 568–574 (2004).

  12. 12

    Shuker, S.B., Hajduk, P.J., Meadows, R.P. & Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531–1534 (1996).

  13. 13

    St. Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197–1202 (2000).

  14. 14

    Huminiecki, L. & Bicknell, R. In silico cloning of novel endothelial-specific genes. Genome Res. 10, 1796–1806 (2000).

  15. 15

    Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364–366 (1996).

  16. 16

    Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377–380 (1998).

  17. 17

    Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629–635 (2004).

  18. 18

    Rybak, J.N. et al. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat. Methods 2, 291–298 (2005).

  19. 19

    Rybak, J.N., Scheurer, S.B., Neri, D. & Elia, G. Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics 4, 2296–2299 (2004).

  20. 20

    Zardi, L. et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6, 2337–2342 (1987).

  21. 21

    Pini, A. et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273, 21769–21776 (1998).

  22. 22

    Castellani, P. et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161, 1695–1700 (2002).

  23. 23

    Borsi, L. et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102, 75–85 (2002).

  24. 24

    Berndorff, D. et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin. Cancer Res. 11, 7053s–7063s (2005).

  25. 25

    Carnemolla, B. et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99, 1659–1665 (2002).

  26. 26

    Ebbinghaus, C. et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer 116, 304–313 (2005).

  27. 27

    Menrad, A. & Menssen, H.D. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin. Ther. Targets 9, 491–500 (2005).

Download references

Acknowledgements

We are grateful to the Functional Genomics Center Zurich for access to mass spectrometers and support. Financial support from the EU project STROMA, the Bundesamt für Bildung und Wissenschaft (FLUOR-MMPI and STROMA), the Swiss National Science Foundation and the Gebert-Rüf Foundation are gratefully acknowledged.

Author information

The study was designed and the paper written by D.N., C.R. and J.-N.R.; experiments were performed by J.-N.R. and C.R.

Correspondence to Christoph Roesli or Jascha-N Rybak.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Roesli, C., Neri, D. & Rybak, J. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. Nat Protoc 1, 192–199 (2006). https://doi.org/10.1038/nprot.2006.29

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.